These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 37627109)

  • 21. Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges.
    Huang WK; Wu CE; Wang SY; Chang CF; Chou WC; Chen JS; Yeh CN
    Curr Treat Options Oncol; 2022 Sep; 23(9):1303-1319. PubMed ID: 35976553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy.
    George S; Jones RL; Bauer S; Kang YK; Schöffski P; Eskens F; Mir O; Cassier PA; Serrano C; Tap WD; Trent J; Rutkowski P; Patel S; Chawla SP; Meiri E; Gordon M; Zhou T; Roche M; Heinrich MC; von Mehren M
    Oncologist; 2021 Apr; 26(4):e639-e649. PubMed ID: 33453089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward.
    Lostes-Bardaji MJ; García-Illescas D; Valverde C; Serrano C
    Ther Adv Med Oncol; 2021; 13():1758835920986498. PubMed ID: 33473249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gastrointestinal stromal tumor: a review of current and emerging therapies.
    Al-Share B; Alloghbi A; Al Hallak MN; Uddin H; Azmi A; Mohammad RM; Kim SH; Shields AF; Philip PA
    Cancer Metastasis Rev; 2021 Jun; 40(2):625-641. PubMed ID: 33876372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
    Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
    Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
    Wilson J; Connock M; Song F; Yao G; Fry-Smith A; Raftery J; Peake D
    Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Gastrointestinal stromal tumour (GIST): current standards in multimodal management].
    Reichardt P; Reichardt A
    Zentralbl Chir; 2011 Aug; 136(4):359-63. PubMed ID: 21863513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical model-based evaluation of Imatinib resistance induced by
    Zhao Q; Zhang C; Qi C; Yang J; Chen Y; Ge S; Shen L; Gao J; Li J
    Am J Transl Res; 2021; 13(12):13608-13624. PubMed ID: 35035701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surgical Management of Metastatic Gastrointestinal Stromal Tumors.
    Yonkus JA; Alva-Ruiz R; Grotz TE
    Curr Treat Options Oncol; 2021 Mar; 22(5):37. PubMed ID: 33743084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors.
    Sargsyan A; Kucharczyk MA; Jones RL; Constantinidou A
    Expert Rev Gastroenterol Hepatol; 2023 Feb; 17(2):119-127. PubMed ID: 36644853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.
    Farag S; Somaiah N; Choi H; Heeres B; Wang WL; van Boven H; Nederlof P; Benjamin R; van der Graaf W; Grunhagen D; Boonstra PA; Reyners AK; Gelderblom H; Steeghs N
    Eur J Cancer; 2017 May; 76():76-83. PubMed ID: 28284172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series.
    Rutkowski P; Magnan H; Chou AJ; Benson C
    BMC Cancer; 2017 Nov; 17(1):717. PubMed ID: 29110655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
    Mir O; Cropet C; Toulmonde M; Cesne AL; Molimard M; Bompas E; Cassier P; Ray-Coquard I; Rios M; Adenis A; Italiano A; Bouché O; Chauzit E; Duffaud F; Bertucci F; Isambert N; Gautier J; Blay JY; Pérol D;
    Lancet Oncol; 2016 May; 17(5):632-41. PubMed ID: 27068858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib.
    Di Vito A; Ravegnini G; Gorini F; Aasen T; Serrano C; Benuzzi E; Coschina E; Monesmith S; Morroni F; Angelini S; Hrelia P
    Pharmacol Ther; 2023 Aug; 248():108475. PubMed ID: 37302758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.
    Smrke A; Gennatas S; Huang P; Jones RL
    Future Oncol; 2020 Aug; 16(22):1639-1646. PubMed ID: 32517495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review.
    Zhang Y; Huang Z
    Front Pharmacol; 2023; 14():1122885. PubMed ID: 37288114
    [No Abstract]   [Full Text] [Related]  

  • 39. The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours.
    Foo T; Goldstein D; Segelov E; Shapiro J; Pavlakis N; Desai J; Yip D; Zalcberg J; Price TJ; Nagrial A; Chantrill L; Burge M; Karapetis CS; Tebbutt N; Roy AC
    Target Oncol; 2022 Mar; 17(2):95-110. PubMed ID: 35290591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
    Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.